

7. Literaturverzeichnis

1. Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. *Lancet* 1997;349:1498-1504
2. Pasternak RC, Criqui MH, Benjamin EJ et al. Atherosclerotic Vascular Disease Conference. Writing Group I: epidemiology. *Circulation* 2004;109:2605-2612
3. Fine-Edelstein JS, Wolf PA, O'Leary DH, et al. Precursors of extracranial carotid atherosclerosis in the Framingham Study. *Neurology* 1994;44:1046-1050
4. The European Carotid Surgery Trialists Collaborative Group. Endarterectomy for moderate symptomatic carotid stenosis: final results from MRC European Carotid Surgery Trial. *Lancet* 1998;351:1379-1387
5. The North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. *N Eng J Med* 1991;325:505-507
6. Inzitari D, Eliasziw M, Gates P, et al. The causes and risk of stroke in patients with asymptomatic internal-carotid-artery stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *N Eng J Med* 2000;342:1693-1700
7. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for Asymptomatic Carotid Atherosclerosis Study. *JAMA* 1995;273:1421-1428
8. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. *N Eng J Med* 1999;340:14-22
9. Bengtsson H, Bergqvist D, Sternby NH. Increasing prevalence of abdominal aortic aneurysms. A necropsy study. *Eur J Surg* 1992;158:19-23
10. Lederle FA, Johnson GR, Wilson SE, et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. *Ann Intern Med* 1997;126:441-449
11. Brady AR, Fowkes FG, Thompson SG, et al. Aortic aneurysm diameter and risk of cardiovascular mortality. *Arterioscler Thromb Vasc Biol* 2001;21:1203-1207
12. Fazio GP, Redberg RF, Winslow T, et al. Transesophageal echocardiographically detected atherosclerotic aortic plaque is a marker for coronary artery disease. *J Am Coll Cardiol* 1993;21:144-150
13. Agmon Y, Khandheria BK, Meissner I, et al. Independent association of high blood pressure and aortic atherosclerosis: A population-based study. *Circulation* 2000;102:2087-2093
14. Agmon Y, Khandheria BK, Meissner I, et al. Relation of coronary artery disease and cerebrovascular disease with atherosclerosis of the thoracic aorta in the general population. *Am J Cardiol* 2002;89:262-267
15. Tunick PA, Rosenzweig BP, Katz ES, et al. High risk for vascular events in patients with protruding aortic atheromas: a prospective study. *J Am Coll Cardiol* 1994;23:1085-1090

16. Witteman JC, Kannel WB, Wolf PA, et al. Aortic calcified plaque and cardiovascular disease (the Framingham Study). *Am J Cardiol* 1990;66:1060-1064
17. Witteman JC, Kok FJ, van Saase JL, et al. Aortic calcification as a predictor of cardiovascular mortality. *Lancet* 1986;2:1120-1122
18. Safian RD, Textor SC. Renal artery stenosis. *N Eng J Med*. 2001;344:431-442
19. Conlon PJ, O`Riordan E, Kalra PA. New insight into the epidemiologic and clinical manifestations of atherosclerotic renovascular disease. *American Journal of Kidney Diseases* 2000;35:573-587
20. Missouris CG, Buckenham T, Vallance PJ, et al. Renal artery stenosis masquerading as congestive heart failure. *Lancet* 1993;341:1521-1522
21. Textor SC: Progressive hypertension in a patient with „incidental“ renal artery stenosis. *Hypertension* 2002;40:595-600
22. Pickering TG. Renovascular hypertension: Medical evaluation and non-surgical treatment, in Laragh JH, Brenner BM (eds): *Hypertension*. New York, NY, Raven Press, 1990,pp1539-1560
23. Greco BA, Breyer JA. The natural history of renal artery stenosis: who should be evaluated for suspected ischemic nephropathy? *Seminars in Nephrology*, 1996;16:2-11
24. Blum U, Krumme B, Flugel P, et al. Treatment of ostial renal artery stenoses with vascular endoprotheses after unsuccessful balloon angioplasty. *N Eng J Med* 1997;336:459-465
25. Hanovici H, Zinicola N: Experimental renal-artery stenosis diagnostic significance of arterial hemodynamics. *J Cardio-vasc Surg* 1962;3:259-262
26. Svetkey LP, Himmelstein SI, Dunnick NR, et al. Prospective analysis of strategies for diagnosing renovascular hypertension. *Hypertension* 1989;14:247-257
27. Scoble Je: The epidemiology and clinical manifestation of atherosclerotic renal disease, in Novivk A, Scoble J, Hamilton G (eds): *Renal Vascular Disease*. London, England. Saunders, 1996, pp303-314
28. Zoccali C, Mallamaci F, Finocchiaro P. Atherosclerotic renal artery stenosis: epidemiology, cardiovascular outcomes, and clinical prediction rules. *J Am Soc Nephrol* 2002;13:179-183
29. Harding MB, Smith LR, Himmelstein SI, et al. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. *J Am Soc Nephrol* 1992;2:1608-1616
30. MacDowall P, Kalra PA, O`Donoghue DJ, et al. Risk of morbidity from renovascular disease in elderly patients with congestive cardiac failure. *Lancet* 1998;352:13-16
31. Krijnen P, van Jaarsfeld BC, Steyerberg EW, et al. A clinical prediction rule for renal artery stenosis. *Ann Int Med* 1998;129:705-711
32. Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. *Ann Int Med* 1993;118:712-719
33. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). *Lancet* 1997;349:747-752
34. Mailloux LU, Napolitano B, Bellucci AG, et al. Renal vascular disease causing end-stage renal disease, incidence, clinical correlates, and outcomes: a 20-year clinical experience. *Am J Kidney Dis* 1994;24:622-629

35. Preston RA, Epstein M: Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. *J Hypertens* 1997;15:1365-1377
36. Uzu T, Takeji M, Yamada N, et al. Prevalence and outcome of renal artery stenosis in atherosclerotic patients with renal dysfunction. *Hypertens Res* 2002;25:537-542
37. Crowley JJ, Santos RM, Peter RH, et al. Progression of renal artery stenosis in patients undergoing cardiac catheterization. *Am Heart J* 1998;136:913-918
38. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. *Circulation* 1998;98:2866-2872
39. Caps MT, Zierler RE, Polissar NL, et al. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. *Kidney Int* 1998;53:735-742
40. Vidt DG. Renal disease and renal artery stenosis in the elderly. *Am J Hypertension* 1998;11:46S-51S
41. Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. *Kidney Int* 2000;58:353-362
42. McCullough PA. Cardiorenal risk: an important clinical intersection. *Rev Cardiovasc Med* 2002;3:71-76
43. Gibson CM, Pinto DS, Murphy SA, et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. *J Am Coll Cardiol* 2003;42:1535-1543
44. French WJ, Wright RS. Renal insufficiency and worsened prognosis with STEMI: a call for action. *J Am Coll Cardiol* 2003;42:1544-1546
45. Arant CB, Wessel TR, Olson MB, et al. Hemoglobin level is an independent predictor for adverse cardiovascular outcomes in women undergoing evaluation for chest pain. *J Am Coll Cardiol* 2004;43:2009-2014
46. Weiner DE, Tighiouart H, Stark PC, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol* 2004;15:1307-1315
47. Weiner DE, Tighiouart H, Amin MG, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. *Am J Kidney Dis* 2004;44:198-206
48. Knight EL, Rimm EB, Pai JK, et al. Kidney dysfunction, inflammation, and coronary events: a prospective study. *J Am Soc Nephrol* 2004;15:1897-1903
49. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. *Acta Med Scand* 1982;211:249-256
50. Cimminiello C. PAD. Epidemiology and pathophysiology. *Thrombosis Research* 2002;106:V295-V301
51. Greenland P, Abrams J, Aurigemma GP, et al. Prevention Conference V: Beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. *Circulation* 2000;101:e16-e22
52. Diehm C, Schuster A, Allenberg J, et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study. *Atherosclerosis* 2004;172:95-105
53. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. *Circulation* 1985;71:510-515

54. Bots ML, Hofman A, Grobbee DE. Common carotid intima-media thickness and lower extremity arterial atherosclerosis. The Rotterdam study. *Arterioscler Thromb Vasc Biol* 1994;14:1885-1891
55. Stoffers HE, Rinkens PE, Kester AD, et al. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. *Int J Epidemiol* 1996;25:282-290
56. Heidrich H, Wenk R, Hesse P. Frequency of asymptomatic peripheral arterial disease in patients entering the department of general and internal medicine of a general-care hospital. *Vasa* 2004;33:63-67
57. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. *Int J Epidemiol* 1991;20:384-392
58. Brevetti G, Oliva G, Silvestro A, et al. Prevalence, risk factors and cardiovascular comorbidity of symptomatic peripheral arterial disease in Italy. *Atherosclerosis* 2004;175:131-138
59. Eickhoff JH, Hansen HJ, Lorentzen JE. The effect of arterial reconstruction on lower limb amputation rate. *Acta Chir Scand Suppl.* 1980;502:181-187
60. Baumgartner I, Schainfeld R, Graziani L. Management of peripheral vascular disease. *Annu Rev Med* 2005;56:249-272
61. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. *N Eng J Med* 1992;326:381-385
62. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. *Atherosclerosis* 1991;87:119-128
63. Transatlantic Intersociety Consensus (TASC) Management of peripheral arterial disease (PAD). *J Vasc Surg* 2000;31:1-296
64. Kampozinski RF, Benrhard VM. Introduction and general considerations. In: *Vascular Surgery*. Rutherford RB ed. WB Saunders, Philadelphia 1989; chapter 53 pp.
65. Hertzner NR, Beven EG, Young JR, et al. Coronary artery disease in peripheral vascular patients: a classification of 1000 coronary angiograms and results of surgical management. *Ann Surg* 1984;199:223-233
66. Dormandy J, Mahir M, Ascady G, et al. Fate of patients with chronic leg ischemia. A review article. *J cardiovasc Surg (Torino)* 1989;30:50-57
67. Eagle KA, Rihal C, Foster ED, et al. Long-term survival in patients with coronary artery disease: importance of peripheral vascular disease. *J Am Coll Cardiol* 1994;23:1091-1095
68. Lanzer P. Vascular multimorbidity in patients with a documented coronary artery disease. *Z Kardiol* 2003;92:650-659
69. Lekakis JP, Papamichael CM, Cimponeriu AT, et al. Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis. *Am J Cardiol* 2000;85:949-952
70. Khoury Z, Schwartz R, Gottlieb S, et al. Relation of coronary artery disease to atherosclerotic disease in the aorta, carotid, and femoral arteries evaluated by ultrasound. *Am J Cardiol* 1997;80:1429-1433
71. Sukhija R, Yalamanchili K, Aronow WS. Prevalence of left main coronary artery disease, of three- or four-vessel coronary artery disease, and of obstructive coronary artery disease in patients with and without peripheral arterial disease undergoing coronary angiography for suspected coronary artery disease. *Am J Cardiol* 2003;92:304-305

72. Burek KA, Sutton-Tyrrell K, Brooks MM, et al. Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). *J Am Coll Cardiol* 1999;34:716-721
73. Varnauskas E, and the European Coronary Surgery Study Group. Twelve-year follow-up survival in the randomized European coronary surgery study. *N Eng J Med* 1988;319:332-337
74. Sutton-Tyrrell K, Rihal C, Sellers A, et al. Long-term prognostic value of clinically evident noncoronary vascular disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). *Am J Cardiol* 1998;81:375-381
75. Cotter G, Cannon CP, McCabe CH, et al. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndrome: are we doing enough? Results from the Orfiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. *Am Heart J* 2003;145:622-627
76. Chiu JH, Topol EJ, Whitlow PL, et al. Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. *Am J Cardiol* 2003;92:582-583
77. Huh J, Wall MJ Jr, Soltero ER. Treatment of combined coronary and carotid artery disease. *Current Opin Cardiol* 2003;18:447-453
78. Schwartz LB, Bridgman AH, Kieffer RW, et al. Asymptomatic carotid artery stenosis and stroke in patients undergoing cardiopulmonary bypass. *J Vasc Surg* 1995;21:146-153
79. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary artery bypass surgery. *N Eng J Med* 1996;335:1857-1863
80. Gardner TJ, Horneffer PJ, Manolio TA, et al. Stroke following coronary artery bypass grafting: a ten-year study. *Ann Thorac Surg* 1985;40:574-578
81. Nallamothu BK, Chetcuti S, Mukherjee D, et al. Long-term prognostic implication of extracardiac vascular disease in patients undergoing percutaneous coronary intervention. *Am J Cardiol* 2003;92:964-966
82. Boushey CJ, Beresford SA, Omenn GS, et al. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA* 1995;274:1049-1057
83. Hennerici M, Aulich A, Sandmann W, et al. Incidence of asymptomatic extracranial arterial disease. *Stroke* 1981;12:750-758
84. Smith I, Franks PJ, Greenhalgh RM, et al. The influence of smoking cessation and hypertriglyceridaemia on the progression of peripheral arterial disease and the onset of critical ischemia. *Eur J Vasc Endovasc Surg* 1996;11:402-408
85. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). *Lancet* 1996;348:1329-1339
86. Ouriel K. Peripheral arterial disease. *Lancet* 2001;358:1257-1264
87. Missouris CG, Buckenham T, Cappuccio FP, et al. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. *Am J Med* 1994;96:10-14

88. Dean RH, Kieffer RW, Smith BM, et al. Renovascular hypertension: anatomic and renal function changes during drug therapy. *Arch Surg* 1981;116:1408-1415
89. Holley KE, Hunt JC, Brown AL Jr, et al. Renal artery stenosis. A clinical-pathologic study in normotensive and hypertensive patients. *Am J Med* 1964;37:14-22
90. Jean WJ, al-Bitar I, Zwicke DL, et al. High incidence of renal artery stenosis in patients with coronary artery disease. *Cath Cardiovasc Diagn.* 1994;32:8-10
91. Valentine RJ, Clagett GP, Miller GL, et al. The coronary risk of unsuspected renal artery stenosis. *J Vasc Surg* 1993;18:433-440
92. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis* 1998;32:112-119
93. Dietz R, v. Harsdorf R, Gross CM, et al. Angiotensin II and coronary artery disease, congestive heart failure and sudden cardiac death. *Basic Res Cardiol* 1998;93:101-108
94. Unger T. The role of the Renin-Angiotensin System in the development of cardiovascular disease. *Am J Cardiol* 2002;89(suppl):3A-10A
95. Romero JC, Reckelhoff JF. The role of angiotensin and oxidative stress in essential hypertension. *Hypertension* 1999;34:943-949
96. Welsh WJ. The pathophysiology of renin release in renovascular hypertension. *Seminars in Nephrology* 2000;20:394-401
97. Admiraal PJ, Derkx FH, Danser AH, Pieterman H, Schalekamp MA. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. *Hypertension* 1990;15:44-55
98. Danser AH, Koning MM, Admiraal PJ, Sassen LM, Derkx FH, Verdouw PD, Schalekamp MA. Production of angiotensins I and II at tissue sites in intact pigs. *Am J Physiol* 1992;263:H429-37
99. Kohara K, Brosnihan KB, Ferrario CM. Peripheral and central angiotensin II regulates expression of genes of the renin-angiotensin system. *Am J Physiol* 1992;262:E651-E657
100. Müller DN, Bohlender J, Hilgers KF, et al. Vascular angiotensin converting enzyme expression regulates local angiotensin II. *Hypertension* 1997;29:98-104
101. Iwai N, Izumi M, Inagami T, et al. Induction of renin in medial smooth muscle cells by balloon injury. *Hypertension* 1997;29:1044-1050
102. Raman VK, Lee YA, Lindpaintner K. The cardiac renin-angiotensin-aldosterone system and hypertensive cardiac hypertrophy. *Am J Cardiol* 1995;76:18D-23D
103. Yang BC, Phillips MI, Mohuczy D, et al. Increased angiotensin II type I receptor expression in hypercholesterolemic atherosclerosis in rabbits. *Arterioscler Thromb Vasc Biol* 1998;18:1433-1439
104. Strawn WB, Chappell MC, Dean RH, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. *Circulation* 2000;101:1586-1593
105. Weiss D, Kools JJ, Taylor WR. Angiotensin II induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. *Circulation* 2001;103:448-454
106. Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. *Circulation* 1997;95:473-478

107. Nickenig G, Jung O, Strehlow K, et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. *Am J Physiol* 1997;272:H2701-2707
108. Morawietz H, Rueckschloss U, Niemann B, et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. *Circulation* 1999;100:899-902
109. Mazzolai L, Duchosal MA, Korber M, et al. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE^{-/-} mice. *Hypertension* 2004;44:277-282
110. Ram CVS, Clagett P, Radford LR. Renovascular Hypertension. *Seminars in Nephrology* 1995;15:152-174
111. Bijlstra PJ, Pstma CT, de Boo T, et al. Clinical and biochemical criteria in the detection of renal artery stenosis. *Journal of Hypertension* 1996;14:1033-1040
112. Dickinson CJ, Lawrence JR. A slowly developing pressor response to small concentration of angiotensin. Its bearing on the pathogenesis of chronic renal hypertension. *Lancet* 1963;1:1354-1356
113. Lerman LO, Nath KA, Rodriguez-Porcel M, et al. Increased oxidative stress in experimental renovascular hypertension. *Hypertension* 2001;37(part 2):541-546
114. Zou Ai-P, Li N, Cowley Jr AW. Production and actions of superoxide in the renal medulla. *Hypertension* 2001;37(part 2):547-553
115. Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme, ramipril, on cardiovascular events. *N Eng J Med*. 2000;342:145-153
116. Epstein FH. Oxygen renal metabolism. *Kidney Int* 1997;51:381-385
117. Simon G. What is critical renal artery stenosis? Implication for treatment. *AJH* 2000;13:1189-1193
118. Wasser MN, Westenberg J, van der Hulst VPM, et al. Hemodynamic significance of renal artery stenosis: digital subtraction angiography versus systolically gated three-dimensional Phase-Contrast MR Angiography. *Radiology* 1997;202:333-338
119. van Jaarsveld BC, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on the hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. *N Eng J Med* 2000;342:1007-1014
120. Greco BA, Breyer JA: Atherosclerotic ischemic renal disease. *Am J Kidney Dis* 1997;29:167-177
121. Schoenberg SO, Knopp MV, Bock M, et al. Renal artery stenosis: grading of hemodynamic changes with Cine Phase-Contrast MR blood flow measurements. *Radiology* 1997;203:45-53
122. Mayberg MR, Wilson E, Yatsu F et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. *JAMA* 1991;266:3289-3294
123. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trial. *Lancet* 2004;363:1491-1502
124. Rothwell PM, Eliasziw M, Gutnikov SA et al. Analysis of pooled data from the randomized controlled trials of endarterectomy for symptomatic carotid stenosis. *Lancet* 2003;361:107-116

125. Faggioli GL, Curl G, Ricotta JJ: The role of carotid screening before coronary artery bypass. *J Vasc Surg* 1990;12:724-731
126. Hertzner NR, Loop FD, Beven EG, et al. Surgical staging for simultaneous coronary and carotid disease: a study including prospective randomization. *J Vasc Surg* 1989;9:455-463
127. Brenner BJ, Brief DK, Alpert J, et al. The risk of stroke in patients with asymptomatic carotid stenosis undergoing cardiac surgery: a follow up study. *J Vasc Surg* 1987;5:269-279
128. Carrel T, Stillhard G, Turina M, et al. Combined Carotid and Coronary Artery Surgery: early and late results. *Cardiology* 1992;80:118-125
129. Schultz RD, Sterpetti AV, Feldhaus RJ, et al. Early and late results in patients with carotid disease undergoing coronary revascularization. *Ann Thorac Surg* 1988;45:603-609
130. Vermeulen FE, Hammerlijck RP, Defauw JJ, et al. Synchronous operation for ischaemic cardiac and cerebrovascular disease: early results and long term follow-up. *Ann Thorac Surg* 1992;53:381-390
131. Roach GW, Kanchuger M, Mangano CM, et al. Adverse cerebral outcomes after coronary bypass surgery. *N Eng J Med* 1996;335:1857-1863
132. Hertzner NR, Loop FD, Taylor PC, et al. Combined myocardial revascularization and carotid endarterectomy. Operative and late results in 331 patients. *J Thorac Cardiovasc Surg* 1983;85:577-589
133. Minami K, Gawanz M, Ohlmeier H, et al. Management of concomitant occlusive disease of coronary and carotid arteries using cardiopulmonary bypass for both procedures. *J Cardiovasc Surg* 1989;30:723-728
134. Moore WS, Barnett HJM, Beebe HG et al. Guidelines for Carotid Endarterectomy . A Multidisciplinary Consensus Statement From the Ad Hoc Committee, American Heart Association. *Circulation* 1995;91:566-579
135. Endovascular versus surgical treatment in patients with carotid stenosis in the carotid and vertebral artery transluminal angioplasty study (CAVATAS): a randomized trial. *Lancet* 2001;357:1729-1737
136. Mathias K. Ein neuartiges Kathetersystem zur perkutanen transluminalen Angioplastie von Karotisstenosen. *Fortschr Med* 1977;95:1007-1011
137. Mathias K, Mittermayer C, Ensinger H et al. Perkutane Katheterdilatation von Karotisstenosen. *RÖFO* 1980;133:258-261
138. Mathias K. Perkutane transluminale Katheterbehandlung supraaortaler Arterienobstruktionen. *Angio* 1981;3:47-50
139. Roubin GS, Yadav S, Iyer SS et al. Carotid stent-supported angioplasty: a neurovascular intervention to prevent stroke. *Am J Cardiol* 1996;78:8-12
140. Reimers B., Corvaja N, Moshiri S et al. Cerebral protection with filter devices during carotid artery stenting. *Circulation* 2001;104:12-15
141. Mudra H, Ziegler M, Haufe MC et al. Perkutane Karotisangioplastie mit Stentimplantation und Embolieprotektion. *Dtsch Med Wochenschr* 2004;128:790-796
142. Sigwart U., Puel J, Mirkovitch, Joffre F, Kappenberger L, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. *N Eng J Med* 1987;316:701-706
143. Serruys PW., Strauss BH, Beat KJ et al. Angiographic follow-up after placement of a self-expanding coronary artery stent. *N Eng J Med* 1991;324:13-17

144. Schömig A., Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulation therapy after placement of a coronary-artery stent. *N Eng J Med* 1996;334:1084-1090
145. Colombo A., Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 1995;91:1678-1688
146. Serruys PW., Emanuelsson H, van der Giessen W et al. Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study. *Circulation* 1996;93:412-422
147. Alfonso F., Hernandez R, Goicolea J et al. Coronary stenting for acute coronary dissection after coronary angioplasty: implications of residual dissection. *J Am Coll Cardiol* 1994;24:989-995
148. Goy JJ., Eeckhout E, Stauffer JC et al. Emergency endoluminal stenting for abrupt vessel closure following coronary angioplasty: a randomized comparison of the Wiktor and Palmaz-Schatz stent. *Cath Cardiovasc Diagn* 1995;34:128-132
149. Pepine CJ., Holmes DR Jr. Coronary artery stents. *J Am Coll Cardiol* 1996;28:782-794
150. Fishman DL., Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease (STRESS-Trial). *N Eng J Med* 1994;331:496-501
151. Serruys PW., de Jaegere P, Kiemeneij F et al. A Comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease (BENESTENT-Trial). *N Eng J Med* 1994;331:489-495
152. Haude M., Erbel R, Issa H, Meyer J. Quantitative analysis of elastic recoil after balloon angioplasty and after intracoronary implantation of balloon-expandable Palmaz-Schatz stents. *J Am Coll Cardiol* 1993;21:26-34
153. Eekhout E., Kappenberger L, Goy JL. Stents for intracoronary placement: current status and future directions. *J Am Coll Cardiol* 1996;27:757-765
154. Van Belle E., Tio FO, Chen D et al. Passivation of metallic stents after arterial gene transfer of pVEGF165 inhibits thrombus formation and intimal thickening. *J Am Coll Cardiol* 1997;29:1371-1390
155. Hoffman R., Mintz GS, Dussailant GR et al. Patterns and Mechanisms of In-Stent Restenosis. *Circulation* 1996;94:1247-1254
156. Hoffmann R., Mintz GS, Popma JJ et al. Chronic arterial responses to stent implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries. *J Am Coll Cardiol* 1996;28:1134-1139
157. Schwartz RS., Huber KC, Murphy JG et al. Restenosis and proportional neointimal response to coronary artery injury: results in a porcine model. *J Am Coll Cardiol* 1992;19:267-274
158. Glagov S., Weisenberg E, Zarins CK et al. Compensatory enlargement Of human atherosclerotic coronary arteries. *N Eng J Med* 1987;316:1371-1375
159. Strauss BH., Umans VA, van Suylen RJ et al. Directional atherectomy for treatment of restenosis within coronary stents: clinical, angiographic and histologic results. *J Am Coll Cardiol* 1992;20:1465-1473

160. Forrester JS., Fishbein M, Helfant R et al. A paradigm for restenosis based on cell biology: Clues for the development of new preventive therapies. *J Am Coll Cardiol* 1991;17:758-769
161. Carter AJ., Laird JR, Farb A et al. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. *J Am Coll Cardiol* 1994;24:1398-1405
162. Rogers C., Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. *Circulation* 1995;91:2995-3001
163. Handbook of coronary stents. M. Dunitz Publisher, UK; 1996 Editor in chief: PW Serruys
164. Langeveld B, Roks AJ, Tio RA, Voors AA, Zijlstra F, van Gilst WH. Renin-angiotensin system intervention to prevent in-stent restenosis: an unclosed chapter. *J Cardiovasc Pharmacol* 2005;45:88-98
165. Schwartz RS. Pathophysiology of restenosis: interaction of thrombosis, hyperplasia, and/or remodeling. *Am J Cardiol* 1998;81:14E-17E
166. Edelman ER, Rogers C. Pathobiologic responses to stenting. *Am J Cardiol* 1998;81:4E-6E
167. Carter AJ, Laird JR, Farb A, Kufs W, Wortham DC, Virmani R. Morphologic characteristics of lesion formation and time course of smooth muscle cell proliferation in a porcine proliferative restenosis model. *J Am Coll Cardiol* 1994;24:1398-1405
168. Rogers C, Welt FG, Karnovsky MJ, Edelman ER. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. *Arterioscler Thromb Vasc Biol* 1996;16:1312-1318
169. Rogers C, Karnovsky MJ, Edelman ER. Inhibition of experimental neointimal hyperplasia and thrombosis depends on the type of vascular injury and the site of drug administration. *Circulation* 1993;88:1215-1221
170. Rogers C, Parikh S, Seifert P, Edelman ER. Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair. *Circulation* 1996;94:2909-2914
171. Kearney M, Pieczek A, Haley L, et al. Histopathology of in-stent restenosis in patients with peripheral artery disease. *Circulation* 1997;95:1998-2002
172. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. *Am J Cardiol* 1999;84:462-466
173. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. *J Clin Invest* 1994;93:339-346
174. Jandeleit-Dahm K, Burrell LM, Johnston CI, Koch KM. Elevated vascular angiotensin converting enzyme mediates increased neointima formation after balloon injury in spontaneously hypertensive rats. *J Hypertens* 1997;15:643-650
175. Haberbosch W, Bohle RM, Franke FE, et al. The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions. *Atherosclerosis* 1997;130:203-213
176. Prescott MF, Webb RL, Reidy MA. Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. *Am J Pathol* 1991;139:1291-1296

177. Scott-Burden T, Hahn AW, Resink TJ, Buhler FR. Modulation of extracellular matrix by angiotensin II: stimulated glycoconjugate synthesis and growth in vascular smooth muscle cells. *J Cardiovasc Pharmacol* 1990;16 Suppl 4:S36-41
178. Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. *Hypertension* 2000;36:330-336
179. Ruiz-Ortega M, Lorenzo O, Suzuki Y, Ruperez M, Egido J. Proinflammatory actions of angiotensins. *Curr Opin Nephrol Hypertens* 2001;10:321-329
180. Wolf G. Free radical production and angiotensin. *Curr Hypertens Rep* 2000;2:167-173
181. Stoll M, Muscha Stecklings U, Paul M, et al. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. *J Clin Invest* 1995;95:651-657
182. Lucius R, Gallinat S, Rosenstiehl P, et al. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adults rats. *J Exp Med* 1998;188:661-670
183. Nakajima M, Hutchinson HG, Fujinaga M, et al. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. *Proc Natl Acad Sci U S A* 1995;92:10663-10667
184. Munzenmaier DH, Greene AS. Opposing actions of angiotensin II on microvascular growth and arterial blood pressure. *Hypertension* 1996;27:760-765
185. Akishita M, Iwai M, Wu L, et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. *Circulation* 2000;102:1684-1690
186. Kohno M, Ohmori K, Nozaki S, et al. Effects of valsartan on angiotensin II-induced migration of human coronary artery smooth muscle cells. *Hypertens Res* 2000;23:677-681
187. Edelman ER, Roggers C. Hoop dreams. Stents without restenosis. *Circulation* 1996;94:1199-1202
188. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results. Strut thickness effects on restenosis outcome (ISAR-STEREO) Trial. *Circulation* 2001;103:2816-2821
189. Leung DYM, Glagov S, Mathews MB. Cyclic stretching stimulates synthesis of matrix components by arterial smooth muscle cells in vitro. *Science* 1976;191:475-477
190. Ishiwata S, Nakanishi S, Nishiyama S et al. Prevention of restenosis by bezafibrate after successful coronary angioplasty. *Coron-Artery-Dis.* 1995;6:883-889
191. Desmarais RL, Sarembock IJ, Ayers CR et al. Elevated serum lipoprotein (a) is a risk factor for clinical recurrence after coronary balloon angioplasty. *Circulation* 1995;91:1403-1409
192. Violaris AG, Melkert R, Serruys PW. Influence of serum cholesterol and cholesterol subfractions on restenosis after successful coronary angioplasty. A quantitative angiographic analysis of 3336 lesions. *Circulation* 1994;90:2267-2279

193. Roth A, Eshchar Y, Keren G et al. Serum lipids and restenosis after successful percutaneous transluminal coronary angioplasty. Ichiloc Magnesium Study Group. *Am J Cardiol* 1994;73:1154-1158
194. Cooke T, Sheahan R, Foley D et al. Lipoprotein (a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. *Circulation* 1994;89:1593-1598
195. Nakamura Y, Yamaoka O, Uchida K et al. Pravastatin reduces restenosis after coronary angioplasty of high-grade stenotic lesions: results of SHIPS (Shiga Pravastatin Study). *Cardiovasc-Drugs-Ther* 1996;10:475-483
196. O'Keefe JH, Stone GW, McCallister BD Jr. et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. *Am J Cardiol* 1996;15;77:649-652
197. Weintraub WS, Boccuzzi SJ, Klein JL et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. *N Engl J Med* 1994;331:1331-1337
198. Montalescot G, Ankri A, Vicaut E et al. Fibrinogen after coronary angioplasty as a risk factor for restenosis. *Circulation* 1995;92:31-38
199. Huber K, Jorg M, Pobst P et al. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. *Thromb Haemost.* 1992; 67:209-213
200. Ishiwata S, Tukada T, Nakanishi S et al. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. *Am Heart J.* 1997;133:387-392
201. Kotamaki M, Laustiola K, Syvanne M et al. Influence of continued smoking and some biological risk factors on restenosis after percutaneous transluminal coronary angioplasty. *J Intern. Med* 1996;240:293-301
202. Galan KM, Deligonul U, Kern MG et al. Increased frequency of restenosis in patients continuing to smoke cigarettes after percutaneous transluminal coronary angioplasty. *Am-J-cardiol* 1988;61:260-263
203. Piessens JH, Stammen F, Desmet W et al. Immediate and 6-month follow-up results of coronary angioplasty for restenosis: analysis of factors predicting recurrent clinical restenosis. *Am-Heart-J* 1993;126:565-570
204. MacDonald RG, Henderson MA, Hirshfeld JW Jr. et al. Patient-related variables and restenosis after percutaneous transluminal coronary angioplasty-- a Report from the M-Heart Group. *Am J Cardiol* 1990;66:926-931
205. Weintraub WS, Kosinski AS, Brown CL 3rd, King SB 3rd. Can restenosis after coronary angioplasty be predicted from clinical variables? *J Am Coll Cardiol* 1993;21:6-14
206. Califf RM, Fortin DF, Frid DJ et al. Restenosis after coronary angioplasty: an overview. *J Am Coll Cardiol* 1991;17:2B-13B
207. Leimgruber PP; Roubin GS, Hollman J et al. Restenosis after successful coronary angioplasty in patients with single vessel disease. *Circulation* 1986;73:710-717
208. Versaci F, Gaspardone A, Tomai F et al. A comparison of coronary artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. *N Eng J Med* 1997;336:817-822

209. Serruys PW, Umans V, Heyndrickx GR et al. Elective PTCA of totally occluded coronary arteries not associated with acute myocardial infarction: short-term and long-term results. *Eur Heart J* 1985;6:2-12
210. Kereiakes DJ, Welmon MR, McAuley et al. Angioplasty in total coronary artery occlusion: experience in 76 consecutive patients. *J Am Coll Cardiol* 1985;6:526-533
211. Hamm CW, Kupper W, Kuck KH et al. Recanalization of chronic totally occluded coronary arteries by new angioplasty systems. *Am J Cardiol* 1990;66:1459-1463
212. Puma JA, Sketch MH Jr, Tchong JE et al. Percutaneous revascularization of chronic coronary occlusions: an overview. *J Am Coll Cardiol* 1995;26:1-11
213. Goldberg SL, Colombo A, Maiello L et al. Intracoronary stent insertion after balloon angioplasty of chronic total occlusions. *J Am Coll Cardiol* 1995;26:713-719
214. Schömig A, Kastrati A, Dietz R et al. Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: angiographic follow-up after stenting and after repeat angioplasty of the Stented Segment. *J Am Coll Cardiol* 1994;23:1053-1060
215. Urban P, Sigwart U, Golf S et al. Intravascular stenting for stenosis of aortocoronary venous bypass grafts. *J Am Coll Cardiol* 1989;13:1085-1091
216. Wong SC, Baim DS, Schatz RA et al. Immediate results and late outcomes after stent implantation in saphenous vein graft lesions: the multicenter U.S. Palmaz-Schatz stent experience. *J Am Coll Cardiol* 1995;26:704-712
217. Mintz G, Popma JJ, Pichard AD et al. Intravascular ultrasound predictors of restenosis after percutaneous coronary revascularization. *J Am Coll Cardiol* 1996;27:1678-1687
218. Hirshfeld JW, Schwartz JS, Jugo R et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-Heart Investigators. *J Am Coll Cardiol* 1991;18:647-656
219. Moscucci M, Piana RN, Kuntz RE et al. Effect of prior coronary restenosis on the risk of subsequent restenosis after stent placement or directional atherectomy. *Am J Cardiol* 1994;73:1147-1153
220. Strauss BH, Serruys PW, de Scheerder IK et al. Relative risk analysis of angiographic predictors of restenosis within the coronary wallstent. *Circulation* 1991;84:1636-1643
221. The Epic investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. *N Eng J Med* 1994;330:956-961
222. The Capture Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the Capture Study. *Lancet* 1997;349:1429-1435
223. Lefkovits J, Blankenship JL, Anderson KM, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. *Am J Cardiol* 1996;77:1045-1051

224. Colombo A, Hall P, Nakamura S et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. *Circulation* 1995;91:1676-1688
225. Serruys PW, Lijten HE, Beatt KJ et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. *Circulation* 1988;77:361-371
226. Hoffmann R, Mintz GS, Dussailant GR et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. *Circulation* 1996;94:1247-1254
227. Windecker S, Mayer I, De Pasquale G, et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. *Circulation* 2001;104:928-933
228. Fry ET, Hermiller JB, Pinkerton CA. New intracoronary stent designs: form follows function versus function follows form. *Curr Opin Cardiol* 1998;13:232-239
229. Ross R. Atherosclerosis is an inflammatory disease. *Am Heart J* 1999;138:S419-420
230. Mayr M, Kiechl S, Willeit J, et al. Infections, immunity, and atherosclerosis: associations of antibodies to *Chlamydia pneumoniae*, *Helicobacter pylori*, and cytomegalovirus with immune reactions to heat-shock protein 60 and carotid or femoral atherosclerosis. *Circulation* 2000;102:833-839
231. Hammann L, Gomma A, Schroeder NW, et al. A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis. *J Mol Med* 2005;83:478-485
232. Hornung V, Rothenfusser S, Britsch S, et al. Quantitative expression of Toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. *J Immunol* 2002;168:4531-4537
233. Lazarus R, Klimecki WT, Raby BA, et al. Single-nucleotide polymorphisms in the Toll-like receptor 9 gene (TLR9): frequencies, pairwise linkage disequilibrium, and haplotypes in three U.S. ethnic groups and exploratory case-control disease association studies. *Genomics* 2003;81:85-91
234. Gearing AJ, Hemingway I, Pigott R, et al. Soluble forms of vascular adhesion molecules, E-selectin, ICAM-1, and VCAM-1: pathological significance. *Ann NY Acad Sci* 1992;667:324-331
235. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary artery disease cases: the Atherosclerosis Risk In Communities (ARIC) study. *Circulation* 1997;96:4219-4225
236. Belch JJ, Shaw JW, Kirk G, et al. The white blood cell adhesion molecule E-selectin predicts restenosis in patients with intermittent claudication undergoing percutaneous transluminal angioplasty. *Circulation* 1997;95:2027-2031
237. Wenzel K, Felix S, Kleber FX, et al. E-selectin polymorphism and atherosclerosis: an association study. *Hum Mol Genet* 1994;3:1935-1937
238. Grewe PH, Deneke T, Machraoui A, et al. Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. *J Am Coll Cardiol* 2000;35:157-163

239. Reilly CF, Kindy MS, Brown KE, et al. Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. *Biol Chem* 1989;264:6990-6995
240. Macejak D, Lin H, Webb S, et al. Adenovirus-mediated expression of a ribozyme to c-myc mRNA inhibits smooth muscle cell proliferation and neointima formation in vivo. *J Virol* 1999;73:7745-7751
241. Badiani P, Corbella P, Kiuoussis D, et al. Dominant interfering alleles define a role for c-Myb in T-cell development. *Genes Dev* 1994;8:770-782
242. Yokota J, Tsunetsugu-Yokota Y, Battifora H, et al. Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. *Science* 1986;231:261-265
243. Kastrati A, Schömig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. *J Am Coll Cardiol* 1997;30:1428-1436
244. Falk E, Shah PK, Fuster V. Coronary plaque disruption. *Circulation* 1995;92:657-671
245. Libby P. Molecular bases of the acute coronary syndromes. *Circulation* 1995;91:2844-2850
246. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. *Lancet* 1994;344:1383-1389
247. Shepard J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. *N Eng J Med* 1995;333:1301-1307
248. Effect on simvastatin on coronary atheroma: the Multicenter Anti-Atheroma Study (MAAS). *Lancet* 1994;344:633-638
249. Jukerna JW, Bruschke AVG, van Bowen AJ, et al. on behalf of the REGRESS Study Group. Effect of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol level. *Circulation* 1995;91:2528-2540
250. Buller CE, Nogareda JG, Ramanathan K, et al. The profile of cardiac patients with renal artery stenosis. *J Am Coll Cardiol* 2004;43:1606-1613
251. Berglund G. Secondary hypertension in the community. In Birkenhager WH, Reid JL Eds. *Handbook of Hypertension*. Amsterdam, Netherlands: Elsevier 1985:249-254
252. Garovic VD, Textor C. Renovascular hypertension and ischemic nephropathy. *Circulation* 2005;112:1362-1374
253. Rajagopalan S, Kurz S, Munzel T et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J Clin Invest* 1996;97:1916-1923
254. Harrison DG. Endothelial function and oxidant stress. *Clin Cardiol* 1997;20(suppl):11-17
255. Patel RP, Moellering D, Murphy-Ullrich J, et al. Cell signaling by reactive nitrogen and oxygen species in atherosclerosis. *Free Radic Biol Med* 2000;28:1780-1794
256. Pueyo ME, Gonzales W, Nicoletti A, et al. Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. *Arterioscler Thromb Vasc Biol* 2000;20:645-651

257. Usui M, Egashira K, Tomita H, et al. Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. *Circulation* 2000;101:305-310
258. Luft FC, Mervaala E, Müller DN, et al. Hypertension-induced end-organ damage: a new approach to an old problem. *Hypertension* 1999;33:212-218
259. Siwik Da, Pagano PJ, Colucci WS. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. *Am J Physiol Cell Physiol* 2001;280:C53-C60
260. Janiszewski M, Pasqualucci CA, Souza LC, et al. Oxidized thiols markedly amplify the vascular response to balloon injury in rabbits through the redox active metal-dependent pathway. *Cardiovasc Res* 1998;39:327-338
261. Funk RC, Wilke A, Rupp H, et al. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. *Adv Exp Med Biol* 1997;432:35-44
262. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. *Circ Res* 2000;86:494-451
263. Hsieh HJ, Cheng CC, Wu ST, et al. Increase of reactive oxygen species in endothelial (ROS) cells by shear flow and involvement of ROS in shear-induced c-fos expression. *J Cell Physiol* 1998;175:156-162
264. Abe J, Berk BC. Fyn and JAK2 mediate RAS activation by reactive oxygen species. *J Biol Chem* 1999;274:21003-21010
265. Kawakami M, Okabe E. Superoxide anion radical-triggered Ca²⁺ release from cardiac sarcoplasmic reticulum through ryanodine receptor Ca²⁺ channel. *Mol Pharmacol* 1998;53:497-503
266. Ushio-Fukai M, Wayne Alexander R, Akers M, et al. p38 Mitogen-activated protein kinase is a critical component of the redox-sensitive signaling pathways activated by angiotensin II. Role in vascular smooth muscle cell hypertrophy. *J Biol Chem* 1998;273:15022-15029
267. Ushio-Fukai M, Wayne Alexander R, Akers M, et al. Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. *J Biol Chem* 1999;274:22699-22704
268. Griendling KK, Miniera CA, Ollerenshaw JD, et al. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured smooth muscle cells. *Circ Res* 1994;74:1141-1148
269. Mancini JGB, Henry GC, Macaya C, et al. Angiotensin converting enzyme inhibition with quinapril improves endothelial dysfunction in patients with coronary artery disease. *Circulation* 1996;94:258-265
270. Prasad A, Tupas-Habib T, Schenk WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. *Circulation* 2000;101:2349-2354
271. Keidar S, Attias J. Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathway. *Biochem Biophys Res Commun* 1997;239:63-67
272. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. *Circulation* 2002;105:393-396
273. Teunissen KE, Postma CT, van Jaarsveld BC, et al. Endothelin and active renin levels in essential hypertension and hypertension with renal

- artery stenosis before and after percutaneous transluminal renal angioplasty. *J of Hypertension* 1997;15:1791-1796
274. Tan L-B, Jalil EJ, Pick R, et al. Cardiac myocyte necrosis induced by angiotensin II. *Circ Res* 1991;69:1185-1195
275. Sakai S, Miyauchi T, Kobayashi M, et al. Inhibition of myocardial endothelin pathway improves long term survival in heart failure. *Nature* 1996;384:353-355
276. Sütsch G, Kiowski W, Yan X-W, et al. Short term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. *Circulation* 1998;98:2262-2268
277. Moreau P, dUscio LV, Shaw S, et al. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. *Circulation* 1997;96:1593-1597
278. Ehmke H, Faulhaber J, Münter K, et al. Chronic ETA receptor blockade attenuates cardiac hypertrophy independently of blood pressure effects in renovascular hypertensive rats. *Hypertension* 1999;33:954-960
279. Krum H, Viskoper RJ, Lacouciere Y, et al. Effect of an endothelin-receptor antagonist, bosentan on blood pressure in patients with mild hypertension. *Bosentan Hypertension Investigators. N Eng J Med* 1998;338:784-790
280. Herizi A, Jover B, Bouriquet N, et al. Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. *Hypertension* 1998;31:10-14
281. Muller DN, Mervaala EM, Dechend R, et al. Angiotensin II (AT1) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. *Am J Pathol* 2000;157:111-122
282. Dechend R, Fiebeler A, Park JK, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. *Circulation* 2001;104:576-581
283. Mervaala E, Müller DN, Schmidt F, et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. *Hypertension* 2000;35:587-594
284. Yang BC, Phillips MI, Mohuczy D, et al. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. *Arterioscl Thromb Vasc Biol* 1998;18:1433-1439
285. Metzger R, Bohle RM, Chumachenko P, et al. CD143 in the development of atherosclerosis. *Atherosclerosis* 1999;150:21-31
286. Fukuhara M, Geary RL, Diz DI, et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. *Hypertension* 2000;35:353-359
287. Van der Hulst VP, van Baalen J, Kool LS, et al. Renal artery stenosis: endovascular flow wire study for validation of Doppler ultrasound. *Radiology* 1996;200:165-168
288. Private C, Ravel A, Chirossel P, et al. Endovascular Doppler guide wire in renal arteries: correlation with angiography in 20 patients. *Invest Radiol* 1999;34:530-535
289. Leertouwer TC, Gussenhoven EJ, Bosch JL, et al. Stent placement for renal arterial stenosis: where do we stand? A meta-analysis. *Radiology* 2000;216:78-85

290. Zeller T, Frank U, Müller C, et al. Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. *Circulation* 2003;108:2244-2249
291. Mikhail A, Scoble JE. Progressive renal dysfunction despite successful renal artery angioplasty in a single kidney. *Lancet* 1997;349:926
292. Hallett JW, Textor SC, Kos PB, et al. Advanced renovascular hypertension and renal insufficiency: trends in medical comorbidity and surgical approach from 1970 to 1993. *J Vasc Surg* 1995;21:750-759
293. Higashi Y, Sasaki S, Nakagawa K, et al. Endothelial function and oxidative stress in renovascular hypertension. *N Eng J Med* 2002;346:1954-1962
294. Faggioli GL, Curl G, Ricotta JJ. The role of carotid screening before coronary artery bypass. *J Vasc Surg* 1990;12:724-731
295. Rizzo RJ, Whittemore AD, Couper GS, et al. Combined carotid and coronary revascularization: the preferred approach to the severe vasculopath. *Ann Thorac Med* 1992;54:1099-1109
296. Reed GL 3rd, Singer DE, Picard EH, et al. Stroke following coronary artery bypass surgery: a case-control estimate of the risk from carotid bruits. *N Eng J Med* 1988;319:1246-1250
297. Naylor Ar, Mehta Z, Rothwell PM, et al. Carotid artery disease and stroke during coronary artery bypass: a critical review of the literature. *Eur J Vasc Endovasc Surg* 2000;23:283-294
298. Huh J, Matthew JW Jr, Soltero ER. Treatment of combined coronary and carotid artery disease. *Curr Opinion Cardiol* 2003;18:447-453
299. Das SK, Brow TD, Pepper J. Continuing controversy in the management of concomitant coronary and carotid disease: an overview. *Int J Cardiol* 2000;74:47-65
300. Borger MA, Fremes SE, Weisel RD, et al. Coronary bypass and carotid endarterectomy: does a combined approach increase risk? A metanalysis. *Ann Throac Surg* 1999;68:14-21
301. Yadav JS, Wholey MH, Kuntz RE et al. Protected carotid-artery stenting versus endarterectomy in high-risk patients. *N Engl J Med* 2004;351:1493-1501
302. Nikolaychik V, Sahota H, Keelan MH, et al. Influence of different stent materials on endothelialization in vitro. *J Invasiv Cardiol* 1999;11:410-415
303. Tanigawa N, Sawada S, Kobayashi M, et al. Reaction of the aortic wall to six metallic stents materials. *Acad Radiol* 1995;2:379-384
304. Hehrlein C, Timmermann M, Metz J, et al. Influence of surface texture and charge on the biocompatibility of endovascular stents. *Coron Artery Disease* 1995;6:581-586
305. Barth KH, Virmani R, Froelich J, et al. Paired comparison of vascular wall reactions to Palmaz stents, Strecker tantalum stents, and Wallstents in canine iliaca and femoral arteries. *Circulation* 1996;93:2161-2169
306. Rodgers C, Edelman ER. Endovascular stent design dictates experimental restenosis and thrombosis. *Circulation* 2000;101:812-818
307. Schwartz RS, Huber KC, Murohy JG, et al. Restenosis and proportional neointimal response to coronary artery injury: results in a porcine model. *J Am Coll Cardiol* 1992;19:267-274
308. Kastrati A, Mehilli J, Dirschinger J, et al. Restenosis after coronary placement of various stent types. *Am J Cardiol* 2001;87:34-39

309. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. *N Eng J Med*. 2002;347:185-192
310. Frenette PS, Wagner DD. Insight into selectin function from knock out mice. *Thromb Haemost* 1997;78:60-64
311. Haller H. Endothelial function. General considerations. *Drugs* 1997;53(Suppl. 1):1-10
312. Wagner OF, Jilma B. Putative role of adhesion molecules in metabolic disorders. *Horm Metab Res* 1997;29:627-630
313. O'Brien KD, McDonald TO, Chait A, et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relations to intimal leukocyte content. *Circulation* 1996;93:672-682
314. Mathamati DJ, Bellas RE, Arsura M, et al. A-myb is expressed in bovine vascular smooth muscle cells during the late G1-to-S-phase transition and cooperates with c-myb to mediate progression to S-phase. *Mol Cell Biol* 1997;17:2448-2457
315. Eltchaninoff H, Koning R, Tron C, et al. Balloon angioplasty for the treatment of coronary in-stent restenosis: Immediately results and 6-month angiographic recurrent restenosis rate. *J Am Coll Cardiol* 1998;32:980-984
316. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schömig A. Vessel size and long-term outcome after coronary stent placement. *Circulation*. 1998;98:1875-1880
317. Condado JA, Waksman R, Gurdiel O, et al. Long-term Angiographic and Clinical Outcome After Percutaneous Transluminal Coronary Angioplasty and Intracoronary Radiation Therapy in Humans. *Circulation* 1997;96:727-732
318. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. *N Engl J Med* 2002;346:1773-1780
319. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. *N Engl J Med* 2004;350:221-231
320. Pharmacological - in-stent restenosis prevention. In: *Randomized Trials Interventional Cardiology 1997-2004*. Eds. Rensing BJ, Vos J, de Fyter Pim J.
321. Peters RJ, Kok WE, Havenith MG, et al. Histopathologic validation of intracoronary ultrasound imaging. *J Am Soc Echocardiography* 1994;7:230-241